Allogeneic Regulatory T cells (Tregs)

Within the CytoSage Team there are many decades of clinical cell therapy development experience. This expertise extends through conduct of phase 1 to 3 clinical trials in anti-inflammatory cell therapy in CNS trauma and stroke and secondary consequences of trauma, such as acute respiratory distress syndrome (ARDS). CytoSage will be developing a novel clinical Treg cell therapy candidate for treatment of the CNS-lesioned patient population. CytoSage have access to a continued source of thymic regulatory T cells (Tregs) for generation of an allogeneic cell therapy and GMP facilities for clinical cell therapy development through clinical stage. 

Proprietary Technology

CytoSage has in-licensed novel, proprietary, ultra high sensitivity multiplex proteomic assay technology, to refine patient stratification with respect to their capacity to respond to different treatment modalities. 

Immunomodulation and Anti-inflammatory Potency Monitoring

Through their prior experience in anti-inflammatory cell therapy development and human immune cell pharmacology, CytoSage’s cell therapy development already incorporates the necessary expertise to establish Treg potency monitoring across multiple immune cell types.